MedPath

The effect of topical betametazon versus topical tacrolimus 0.1% in the treatment of vitiligo

Phase 3
Conditions
Vitiligo.
Vitiligo
Registration Number
IRCT201311295605N6
Lead Sponsor
Tabriz university of medical sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Patients with vitiligo over 2 years old and less than 30% of body surface area involved.

Exclusion criteria: Patients with allergy or hypersensitivity to macrolides; Pregnant and lactating women; Patients with immune deficiency and patients who had received vitiligo medications less than 6 months ago

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Severity of vitiligo skin lesion. Timepoint: 6 month. Method of measurement: Clinical assesment.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath